BCR-ABL TKIs are the first-line treatment for patients with chronic myelocytic leukemia (CML) and Ph chromosome-positive acute lymphoblastic leukemia (31). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.